OGN

NEUTRALM&A

Organon & Co.

2026-07-07

Price

$13.51

-0.37%

This is the 2026-07-07 snapshot — the signals and analysis for OGN as of this single trading day.

View full OGN research hub →

Score15.5Top Tier

Signals6/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume1.3xvs 20d avg

Analysis

Organon & Co. (OGN) is trading in a tight merger arbitrage pattern because of Sun Pharmaceutical's pending $14.00 per share all-cash acquisition. The ultra-low 3.6% realized volatility and strong technical signals (SURGE, QUIET_STORM) directly reflect institutional arbitrageurs locking in the spread rather than organic price discovery. While the broader market is in a RISK_ON regime ignoring geopolitical flares, OGN's price action is completely insulated from macro beta, offering a high-conviction, low-risk yield play as deal financing is officially secured.

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUE

Key Takeaways

Actionable Thesis: OGN is a pure merger arbitrage play offering a ~3.6% spread up to Sun Pharma's $14.00 all-cash offer, supported by strong institutional accumulation [1.2.1].
Key Risk: Standard shareholder investigations into the acquisition price and potential antitrust or regulatory hurdles before the expected early 2027 close.
What to Watch: Monitor the timeline for shareholder votes and any regulatory approvals, as the newly announced bank financing largely derisks the capital side of the deal.

← Back to 2026-07-07 View Full OGN History →Yahoo Finance &nearr;